Attitudes and practices in the laboratory monitoring of conventional synthetic disease modifying anti-rheumatic drugs by rheumatologists and rheumatology trainees

Table 5 Least severe event regarding ALT/AST monitoring precipitating a change in methotrexate prescription by respondent (%), N = 150^#

Event	Change in prescription	Respondent (N, %)*
Any	None	0 (0%)
< 2ULN ALT/AST	Reduce dose	36 (24%)
< 2ULN ALT/AST	Suspend drug	9 (6%)
2–3 ULN ALT/AST	Reduce dose	29 (19%)
2–3 ULN ALT/AST	Suspend drug	16 (11%)
> 3 ULN ALT/AST	Reduce dose	6 (4%)
> 3 ULN ALT/AST	Suspend drug	12 (8%)
Multiple rising ALT/AST with most recent < 2 ULN ALT/AST	Reduce or suspend drug	19 (13%)
Multiple rising ALT/AST with most recent 2–3 ULN ALT/AST	Reduce or suspend drug	12 (8%)
Multiple rising ALT/AST with most recent > 3 ULN ALT/AST	Reduce or suspend drug	7 (5%)
Other	Individual	4 (3%)

^#Impact of monitoring data unavailable for whole cohort (N = 221)
*Percentages are all rounded to the nearest whole number (including 0 and 100) and thus some differing raw numbers show the same percent and non-0 raw numbers may show 0%

ISSN: 2520-1026